FP1481 : Role of topical Interferon alpha 2b as first line therapy in OSSN.

Dr. Rakhi Kusumesh (K11392)

Purpose: To study the efficacy and safety of topical interferon alpha 2b (IFN a2b) as a first line therapy for primary OSSN.

Methods: Medical records of 29 eyes of 29 patients with diagnosis of primary OSSN were reviewed retrospectively. All cases were treated with topical IFN a2b (1 million IU/ml) 4 times daily. The duration of treatment, tumor response and adverse effects were noted. Results: The complete remission of tumor was observed in 26 patients (89.65%). 3 patients (10.34%) did not respond to the treatment. The mean age was 62.44 ±13.65 years (range, 50-92 years). The mean follow-up period was 23.42 (range, 14-32 months). No long-term complication or recurrence was found at the end of follow-up period.

Conclusions: Topical IFN a2b is effective and safe as a first line therapy in management of primary OSSN with minimal self-limited adverse effects.